LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3046% below fair value
$4.13+0.04 (+0.98%)
Close on Nov 13, 2026Market cap $129.77MP/E –Yield –
LENZ Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
LENZ Therapeutics's enterprise value was -$90.88M on Nov 11, 2026, against $670.31M a year earlier. Over the last 5 years it ranged from -$320.69M to $1.12B, with a median of -$80.31M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$90.88M | -135.6% |
| 2025 | Dec 31, 2025 | $255.21M | -55.7% |
| 2024 | Dec 31, 2024 | $576.17M | – |
| 2023 | Dec 29, 2023 | -$197.34M | – |
| 2022 | Dec 30, 2022 | -$258.50M | – |
| 2021 | Dec 31, 2021 | -$220.55M | – |
See a number that looks wrong?